Media
| Press Releases
KBP Presents Results of the Hepatic Impairment Study and Drug-Drug Interaction S...
PRINCETON, N.J., 30November2022 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a...
Nov 30, 2022
Announcement of Interim Chief Commercial Officer Appointment
PRINCETON, N.J., 15 November, 2022 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or “KBP” or the “...
Nov 16, 2022
Announcement of Deputy Chief Medical Officer Appointment
PRINCETON, N.J., 14 November 2022 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or “KBP” or the “C...
Nov 15, 2022
KBP Biosciences Is Successfully Selected into the “Raffles Family Office · Huru...
KBP Biosciences Co., Ltd. announced it is successfully selected into the “Raffles Family Office · Hu...
Jan 30, 2022
KBP Biosciences Announces First Patient Dosed in KBP-5074 Global Phase 3 Study i...
Dose administration for the first patient in CLARION-CKD (ClinicalTrials.gov Identifier: NCT04968184...
Jan 04, 2022
KBP Biosciences Presentation at the 18th Global CardioVascular Clinical Trialist...
The 18th Global CardioVascular Clinical Trialist Forum was held December 2-5, 2021. The conference g...
Dec 10, 2021